VivoSeq
Metabolic & Endocrine

Insulin Resistance

140

Pipeline Programs↗

23

Active Trials↗

40

Companies Involved↗

Insulin resistance is a highly competitive landscape with 140 programs across 40 companies. The most active players are Fresenius Kabi Oncology Ltd., Xeris Pharmaceuticals, Bristol-Myers Squibb. 34 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

22/100

Mech. Concentration

4/100

Completion Rate

82/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1X

Xeris Pharmaceuticals

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical38

Estradiol

Novo Nordisk

Nicorandil

Merck & Co.

Somatropin

EMD Serono

Losartan

Organon and Co

Heparin

Baxter Healthcare Corporation

Phase 116

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Salsalate

Joslin Diabetes Center

Dexamethasone

Aspen Global Incorporated

Atropine

Fresenius Kabi Oncology Ltd.

Olanzapine

MODAG GmbH

Phase 241

Metreleptin

Chiesi Farmaceutici S.p.A.

Dapagliflozin

AstraZeneca

Resveratrol

National Cancer Institute (NCI)

Ribavirin

Conrado Roberto Hoffmann Filho

Allopurinol

Alnylam Pharmaceuticals

Phase 311

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Metformin Hydrochloride

Boehringer Ingelheim

Sitagliptin

Zydus Therapeutics Inc.

Empagliflozin

Boehringer Ingelheim

Bromocriptine

VeroScience

Approved34

Hydroxychloroquine

Alnylam Pharmaceuticals

Pioglitazone

Takeda

Ergocalciferol

Alnylam Pharmaceuticals

Ramelteon

Takeda

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Analysis

Modality Breakdown

99%

Small molecule

156 of 158 classified programs — the dominant modality here.

1%ALL OTHERSMonoclonal antibody1<1%Peptide1<1%

Small molecule leads; the ring shows all 158 classified programs, each share of the total. Modality classified for 98% of 170 pipeline programs.

Analysis

Trial Status

179

clinical trials

Completed111 · 62%
Unknown status20 · 11%
Withdrawn13 · 7%
Terminated11 · 6%
Recruiting11 · 6%
Active, not recruiting7 · 4%
Other6 · 3%

Clinical Trials

Trial Activity

179 trials

Investigating the Insulin Resistance in Individuals With Type 2 Diabetes
Recruiting·—·N/A·NCT06428968·30 enrolled
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Recruiting·—·Phase 1·NCT06354088·32 enrolled
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
Recruiting·UUniversity of Alberta·Phase 3·NCT04578652·90 enrolled
Acupuncture or Metformin for Insulin Resistance in Women With PCOS
Recruiting·KKarolinska Institutet·Phase 2·NCT02647827·303 enrolled
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
Recruiting·—·Phase 1·NCT07224334·30 enrolled
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT05470504·25 enrolled
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
Recruiting·—·Phase 3·NCT06763328·200 enrolled
Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
Recruiting·—·Phase 1/2·NCT06806345·40 enrolled
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04715022·23 enrolled
The Muscle Phenotype and Cardiometabolic Health Monitoring Project
Recruiting·UUniversity Ghent·N/A·NCT07678736·250 enrolled
Reversal of Lipid-Induced Insulin Resistance
Recruiting·YYale University·Preclinical·NCT02193295·250 enrolled
Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM
Active, not recruiting·—·Phase 4·NCT06860841·16 enrolled
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
Active, not recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00085982·11 enrolled
Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents
Active, not recruiting·CCentre for Addiction and Mental Health·N/A·NCT05571878·24 enrolled
A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance
Active, not recruiting·OOrsoBio, Inc·Phase 2·NCT05665751·76 enrolled
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)